Models for suicide preventions that are easier to explain and use could have better uptake in health care settings. UW Biostatistics Affiliate Faculty Susan Shortreed was lead author on this recent study which compares the performance of 5 different models developed to identify a patient's risk of suicidal behavior.

Mosaic and consensus HIV-1 immunogen vaccines were tested in a clinical trial led by a team of researchers including Drs. Kristen Cohen, Andrew Fiore-Gartland, Peter Gilbert and M. Juliana McElrath from the Fred Hutchinson Cancer Center Vaccine and Infectious Disease Division. Their findings were published recently in the Journal of Clinical Investigation.

Ali Shojaie will be a member of new multidisciplinary, multi-institutional team that recently received a five-year, $4.2 million grant from the National Institutes of Health to develop neural stimulation techniques guided by artificial intelligence (AI) machine learning methods.

Only a handful of scientists at Fred Hutchinson Cancer Center have been around longer than the institution itself; longtime public health researcher Ross Prentice, PhD, who retired at the end of 2022, is one of them.

UW Biostatistics postdoc Lu Xia is first author, and faculty member Ali Shojaie a co-author, of research that found distinct plasma metabolomic profiles are associated with right ventricular dilation, mortality, and measures of disease severity in pulmonary arterial hypertension.

The World Health Organization has a mandate to compile and disseminate statistics on mortality, and we have been tracking the progression of the COVID-19 pandemic since the beginning of 2020. Here we report a comprehensive and consistent measurement of the impact of the COVID-19 pandemic by estimating excess deaths, by month, for 2020 and 2021. 

Researchers have used a new approach to refine the estimate of the average genome-wide mutation rate for humans, which they pegged at 1.24 x 10-8 per base pair per generation.

According to UW Professor of Biostatistics Sharon Browning and her colleagues, the rate they calculated "is consistent with our previous IBD-based estimates but has tighter confidence intervals because of the larger sample size enabled by the methodology presented here."

"Even though (the data) is impressive for a new molecular entity - it has no direct evidence to support the antiviral activity," said panel member Susanne May, who voted against authorization of the drug. May is a professor of biostatistics with the University of Washington School of Public Health and director of the UW Clinical Trials Center.